The Antiandrogen Withdrawal Syndrome in Relapsed Prostate Cancer
- 1 January 1997
- journal article
- Published by Elsevier in European Urology
- Vol. 31 (2) , 3-7
- https://doi.org/10.1159/000474540
Abstract
Evolving data suggest that palliation of relapsed prostate cancer can be achieved by the selective discontinuation of agents that act via steroid hormone receptors. Clinical benefit has been observed following the withdrawal of flutamide (Eulexin, Schering-Plough International), bicalutamide (Casodex, Zeneca Ltd), oestrogens, progestational agents and retinoids. For patients with progression of disease while receiving these drugs, a period of observation after withdrawal should be considered before further therapy is initiated.Keywords
This publication has 0 references indexed in Scilit: